România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
iomeron 300 mg/ml
patheon italia s.p.a. - italia - iomeprolum - sol. inj. - 612,4mg/ml - medii de contrast cu iod pt. radiologie m. de contrast cu iod pt.rx, nefrotopice,hidrosol. cu osm mi
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
iomeron 350 mg/ml
patheon italia s.p.a. - italia - iomeprolum - sol. inj. - 714,4mg/ml - medii de contrast cu iod pt. radiologie m. de contrast cu iod pt.rx, nefrotopice,hidrosol. cu osm mi
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
iomeron 400 mg/ml
patheon italia s.p.a. - italia - iomeprolum - sol. inj. - 816,5mg/ml - medii de contrast cu iod pt. radiologie m. de contrast cu iod pt.rx, nefrotopice,hidrosol. cu osm mi
Uniunea Europeană -
română -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenți antineoplazici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Uniunea Europeană -
română -
EMA (European Medicines Agency)
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
memelin 25 mg
eirgen pharma ltd. - irlanda - exemestanum - compr. film. - 25mg - antagonisti hormonali si substante inrudite inhibitori enzimatici
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
resivirtan 100 mg/ml
aflofarm farmacja polska sp. z o.o. - polonia - inosinum - sirop - 100mg/ml - antivirale cu actiune directa alte antivirale